Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Should You Sell?

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG)’s share price gapped down before the market opened on Tuesday . The stock had previously closed at $28.38, but opened at $27.31. Ascentage Pharma Group International shares last traded at $27.31, with a volume of 633 shares.

Analysts Set New Price Targets

AAPG has been the subject of a number of research analyst reports. Truist Financial set a $51.00 price objective on shares of Ascentage Pharma Group International in a report on Monday, November 24th. Oppenheimer started coverage on shares of Ascentage Pharma Group International in a research report on Thursday, December 4th. They issued an “outperform” rating and a $45.00 target price on the stock. Lucid Cap Mkts raised Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. Piper Sandler began coverage on Ascentage Pharma Group International in a research note on Wednesday, November 5th. They issued an “overweight” rating and a $48.00 target price for the company. Finally, Rodman & Renshaw started coverage on Ascentage Pharma Group International in a research report on Tuesday. They set a “buy” rating and a $48.00 price target on the stock. One research analyst has rated the stock with a Strong Buy rating and six have assigned a Buy rating to the company’s stock. According to MarketBeat.com, Ascentage Pharma Group International currently has a consensus rating of “Buy” and a consensus price target of $48.40.

Ascentage Pharma Group International Trading Down 0.2%

The company has a quick ratio of 1.53, a current ratio of 1.54 and a debt-to-equity ratio of 1.31. The firm’s fifty day moving average is $30.08 and its two-hundred day moving average is $36.09.

Institutional Investors Weigh In On Ascentage Pharma Group International

Several hedge funds have recently made changes to their positions in AAPG. Chevy Chase Trust Holdings LLC bought a new position in Ascentage Pharma Group International in the second quarter worth $227,000. Tema Etfs LLC bought a new stake in shares of Ascentage Pharma Group International during the 2nd quarter valued at $610,000. UBS Group AG grew its position in shares of Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock worth $716,000 after buying an additional 10,988 shares during the period. Hsbc Holdings PLC bought a new position in shares of Ascentage Pharma Group International in the 2nd quarter worth about $391,000. Finally, Citadel Advisors LLC bought a new position in shares of Ascentage Pharma Group International in the 3rd quarter worth about $383,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.